NCT06875076View on ClinicalTrials.gov

Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural Mesothelioma

PHASE2RecruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

March 8, 2025

Primary Completion Date

January 31, 2028

Study Completion Date

December 31, 2029

Conditions
Pretreated Pleural Mesothelioma
Interventions
DRUG

Ivonescimab Combined With Chemotherapy

ivonescimab 20mg/kg combined with pemetrexed 500mg/m²/gemcitabine 1000mg/m²/vinorelbine 25mg/m² every 21 days for 4 cycles followed by a maintenance phase (ivonescimab monotherapy 20mg/kg every 21 days until disease progression, intolerance, or up to 2 years)

Trial Locations (1)

130000

RECRUITING

Cancer center, First Hospital of Jilin University, Changchun

All Listed Sponsors
lead

The First Hospital of Jilin University

OTHER